CIBC Private Wealth Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

CIBC Private Wealth Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$41.3K	Buy	+1,000	New	+$40.1K	﹤0.01%	1859

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

CIBC Private Wealth Group's KNSA Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q4 2025: 1,000 shares worth $41.3K. The stake represents ﹤0.01% of the portfolio and ranks #1859 among its holdings.

224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

CIBC Private Wealth Group held 1,000 shares of Kiniksa Pharmaceuticals worth $41.3K as of Q4 2025.
Kiniksa Pharmaceuticals was a new CIBC Private Wealth Group position in Q4 2025.
Kiniksa Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1859 holding.
224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.